International Murex Technologies (US) launches second-generation HCV test:
This article was originally published in Clinica
Executive Summary
International Murex Technologies (US) has introduced its second-generation HCV serotyping test - initially outside the US. The test has been approved for in vitro diagnostic use in France, Murex notes. The sale of the assay, which covers HCV types 1-6, is "not currently affected by injunctions blocking Murex from manufacturing and selling its anti-HCV screening test", the company says. There are approximately five million confirmed HCV-infected people in Europe, of which 3.4 million have chronic active hepatitis.